Skip to main content
Erschienen in: Endocrine 1/2009

01.08.2009 | Original Article

Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance

verfasst von: Cheril L. Clarson, Farid H. Mahmud, Janet E. Baker, Helen E. Clark, Wendy M. Mckay, Vicki D. Schauteet, David J. Hill

Erschienen in: Endocrine | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

This study assessed the efficacy of adding metformin to a structured lifestyle intervention in reducing BMI in obese adolescents with insulin resistance. Obese adolescents (25) aged 10–16 years with a body mass index (BMI) > 95th percentile and insulin resistance (Homeostasis Model Assessment—HOMA) > 3.0 were assessed in a community clinic. A structured lifestyle intervention comprising nutritional and exercise education and motivational support in both individual and group sessions was delivered over 6 months. Subjects were randomized to lifestyle intervention alone or with metformin (1500 g daily). The primary outcome measures were a change in BMI and modification of metabolic risk factors, including insulin resistance, plasma lipids and adipocytokines. Eleven adolescents receiving lifestyle and metformin intervention and 14 receiving lifestyle alone completed the study. BMI decreased by 1.8 kg/m2 with lifestyle and metformin but did not change with lifestyle alone. HOMA was significantly decreased in the lifestyle intervention group, but not following metformin, while the adiponectin/leptin ratio improved significantly in both groups. Dyslipidemic profiles improved most significantly with metformin. We conclude that metformin in combination with a 6-month structured lifestyle intervention is effective in reducing BMI in obese adolescents but did not improve insulin resistance. Lifestyle intervention, with or without metformin, improved metabolic risk factors such as plasma lipids and adipocytokines.
Literatur
1.
Zurück zum Zitat P.W. Franks, R.L. Hanson, W.C. Knowler et al., Childhood predictors of young—onset type 2 diabetes. Diabetes 56, 2964–2972 (2006)CrossRef P.W. Franks, R.L. Hanson, W.C. Knowler et al., Childhood predictors of young—onset type 2 diabetes. Diabetes 56, 2964–2972 (2006)CrossRef
2.
Zurück zum Zitat S.E. Kahn, R.L. Hull, K.M. Utzschneider, Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840–846 (2006)CrossRefPubMed S.E. Kahn, R.L. Hull, K.M. Utzschneider, Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840–846 (2006)CrossRefPubMed
3.
Zurück zum Zitat S. Arslanian, Type 2 diabetes mellitus in children: pathophysiology and risk factors. J. Pediatr. Endocrinol. Metab. 13, 1385–1394 (2000)PubMed S. Arslanian, Type 2 diabetes mellitus in children: pathophysiology and risk factors. J. Pediatr. Endocrinol. Metab. 13, 1385–1394 (2000)PubMed
4.
Zurück zum Zitat M.S. Tremblay, J.D. Willms, Secular trends in the body mass index of Canadian children. Can. Med. Assoc. J. 163, 1429–1433 (2000) M.S. Tremblay, J.D. Willms, Secular trends in the body mass index of Canadian children. Can. Med. Assoc. J. 163, 1429–1433 (2000)
5.
Zurück zum Zitat A. Fagot-Campagna, D.J. Pettitt, M.M. Engelgau et al., Type 2 diabetes among North American children and adolescents; an epidemiologic review and a public health perspective. J. Pediatr. 136, 664–672 (2000)CrossRefPubMed A. Fagot-Campagna, D.J. Pettitt, M.M. Engelgau et al., Type 2 diabetes among North American children and adolescents; an epidemiologic review and a public health perspective. J. Pediatr. 136, 664–672 (2000)CrossRefPubMed
6.
Zurück zum Zitat H.J. Dean, R.L. Mundy, M. Moffatt, Non-insulin dependent diabetes mellitus in Indian Children in Manitoba. Can. Med. Assoc. J. 147, 52–57 (1992) H.J. Dean, R.L. Mundy, M. Moffatt, Non-insulin dependent diabetes mellitus in Indian Children in Manitoba. Can. Med. Assoc. J. 147, 52–57 (1992)
7.
Zurück zum Zitat R.Y. Sung, P.C. Tong, C.W. Yu et al., High prevalence of insulin resistance and metabolic syndrome in overweight/obese preadolescent Hong Kong Chinese children aged 9–12 years. Diabetes Care 26, 250–251 (2003)CrossRefPubMed R.Y. Sung, P.C. Tong, C.W. Yu et al., High prevalence of insulin resistance and metabolic syndrome in overweight/obese preadolescent Hong Kong Chinese children aged 9–12 years. Diabetes Care 26, 250–251 (2003)CrossRefPubMed
8.
Zurück zum Zitat N. Stefan, J.C. Bunt, A.D. Salbe et al., Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J. Clin. Endocrinol. Metab. 87, 4652–4656 (2002)CrossRefPubMed N. Stefan, J.C. Bunt, A.D. Salbe et al., Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J. Clin. Endocrinol. Metab. 87, 4652–4656 (2002)CrossRefPubMed
9.
Zurück zum Zitat F. Bacha, R. Saad, N. Gungor et al., Adiponectin in youth: relationship to visceral obesity, insulin sensitivity, and beta cell function. Diabetes Care 27, 547–552 (2007)CrossRef F. Bacha, R. Saad, N. Gungor et al., Adiponectin in youth: relationship to visceral obesity, insulin sensitivity, and beta cell function. Diabetes Care 27, 547–552 (2007)CrossRef
10.
Zurück zum Zitat M. Bajaj, S. Suraamornkul, L.J. Hardies et al., Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int. J. Obes. Relat. Metab. Disord. 28, 783–789 (2004)CrossRefPubMed M. Bajaj, S. Suraamornkul, L.J. Hardies et al., Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int. J. Obes. Relat. Metab. Disord. 28, 783–789 (2004)CrossRefPubMed
11.
Zurück zum Zitat L. Gilardini, P.G. McTernan, A. Girola et al., Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis 189, 401–407 (2006)CrossRefPubMed L. Gilardini, P.G. McTernan, A. Girola et al., Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis 189, 401–407 (2006)CrossRefPubMed
12.
Zurück zum Zitat G.Q. Shaibi, M.L. Cruz, M.J. Weigensberg et al., Adiponectin independently predicts metabolic syndrome in overweight Latino youth. J. Clin. Edocrinol. Metab. 92, 1809–1813 (2007)CrossRef G.Q. Shaibi, M.L. Cruz, M.J. Weigensberg et al., Adiponectin independently predicts metabolic syndrome in overweight Latino youth. J. Clin. Edocrinol. Metab. 92, 1809–1813 (2007)CrossRef
13.
Zurück zum Zitat M. Savoye, J. Dziura, J. Castle et al., Importance of plasma leptin in predicting future weight gain in obese children: a two-and-a-half-year longitudinal study. Int. J. Obes. Relat. Metab. Disord. 26, 942–946 (2002)CrossRefPubMed M. Savoye, J. Dziura, J. Castle et al., Importance of plasma leptin in predicting future weight gain in obese children: a two-and-a-half-year longitudinal study. Int. J. Obes. Relat. Metab. Disord. 26, 942–946 (2002)CrossRefPubMed
14.
Zurück zum Zitat J.P. Kay, R. Alemzadeh, G. Langley et al., Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50, 1457–1461 (2001)CrossRefPubMed J.P. Kay, R. Alemzadeh, G. Langley et al., Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50, 1457–1461 (2001)CrossRefPubMed
15.
Zurück zum Zitat M. Freemark, D. Bursey, The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 107, E55 (2001)CrossRefPubMed M. Freemark, D. Bursey, The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 107, E55 (2001)CrossRefPubMed
16.
Zurück zum Zitat S. Srinivasan, G.R. Ambler, L.A. Baur et al., Randomized controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J. Clin. Endocrinol. Metab. 91, 2074–2080 (2006)CrossRefPubMed S. Srinivasan, G.R. Ambler, L.A. Baur et al., Randomized controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J. Clin. Endocrinol. Metab. 91, 2074–2080 (2006)CrossRefPubMed
17.
Zurück zum Zitat K. Love-Osborne, J. Sheeder, P. Zeitler, Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J. Pediatr. 152, 817–822 (2008)CrossRefPubMed K. Love-Osborne, J. Sheeder, P. Zeitler, Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J. Pediatr. 152, 817–822 (2008)CrossRefPubMed
18.
Zurück zum Zitat R.H. Lustig, M.L. Mietus-Snyder, P. Bacchetti et al., Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children. Pediatrics 148, 23–29 (2006)CrossRef R.H. Lustig, M.L. Mietus-Snyder, P. Bacchetti et al., Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children. Pediatrics 148, 23–29 (2006)CrossRef
19.
Zurück zum Zitat B. Schwartz, D.R. Jacobs, A. Moran et al., Measurement of insulin sensitivity in children: comparison between the euglycemic hyperinsulinemic clamp and surrogate measures. Diabetes Care 31, 783–788 (2008)CrossRefPubMed B. Schwartz, D.R. Jacobs, A. Moran et al., Measurement of insulin sensitivity in children: comparison between the euglycemic hyperinsulinemic clamp and surrogate measures. Diabetes Care 31, 783–788 (2008)CrossRefPubMed
20.
Zurück zum Zitat S.D. Ferranti, S.K. Osganian, Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. Diabetes Vasc. Dis. Res. 4, 285–296 (2007)CrossRef S.D. Ferranti, S.K. Osganian, Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. Diabetes Vasc. Dis. Res. 4, 285–296 (2007)CrossRef
21.
Zurück zum Zitat E.S. Kim, J.A. Im, K.C. Kim et al., Improved insulin sensitivity and adiponectin level after exercise training in obese Korean youth. Obesity 15, 3023–3030 (2007)CrossRefPubMed E.S. Kim, J.A. Im, K.C. Kim et al., Improved insulin sensitivity and adiponectin level after exercise training in obese Korean youth. Obesity 15, 3023–3030 (2007)CrossRefPubMed
22.
Zurück zum Zitat E.E. Reiterer, K.M. Sudi, A. Mayer et al., Changes in leptin, insulin and body composition in obese children during a weight reduction program. J. Pediatr. Endocrinol. Metab. 12, 853–862 (1999)PubMed E.E. Reiterer, K.M. Sudi, A. Mayer et al., Changes in leptin, insulin and body composition in obese children during a weight reduction program. J. Pediatr. Endocrinol. Metab. 12, 853–862 (1999)PubMed
23.
Zurück zum Zitat V.M. Cambuli, M.C. Musiu, M. Incani et al., Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children. J. Clin. Edocrinol. Metab. 93, 3051–3057 (2008)CrossRef V.M. Cambuli, M.C. Musiu, M. Incani et al., Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children. J. Clin. Edocrinol. Metab. 93, 3051–3057 (2008)CrossRef
24.
Zurück zum Zitat M. Zeller, S. Kirk, R. Claytor et al., Predictors of attrition from a pediatric weight management program. J. Pediatr. 144, 466–470 (2004)CrossRefPubMed M. Zeller, S. Kirk, R. Claytor et al., Predictors of attrition from a pediatric weight management program. J. Pediatr. 144, 466–470 (2004)CrossRefPubMed
25.
Zurück zum Zitat K.M. Young, J.J. Northern, K.M. Lister, J.A. Drummond, W.H. O’Brien et al., A meta-analysis of family-behavioural weight-loss treatments for children. Clin. Psychol. Rev. 27, 240–249 (2007)CrossRefPubMed K.M. Young, J.J. Northern, K.M. Lister, J.A. Drummond, W.H. O’Brien et al., A meta-analysis of family-behavioural weight-loss treatments for children. Clin. Psychol. Rev. 27, 240–249 (2007)CrossRefPubMed
26.
Zurück zum Zitat N. Gungor, R. Saad, J. Janosky et al., Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J. Pediatr. 144, 47–55 (2004)CrossRefPubMed N. Gungor, R. Saad, J. Janosky et al., Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J. Pediatr. 144, 47–55 (2004)CrossRefPubMed
27.
Zurück zum Zitat M. Keskin, S. Kurtoglu, M. Kendirci et al., Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 115, 500–503 (2005)CrossRef M. Keskin, S. Kurtoglu, M. Kendirci et al., Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 115, 500–503 (2005)CrossRef
28.
Zurück zum Zitat P. Allard, E.E. Delvin, G. Paradis et al., Distribution of fasting plasma insulin, free fatty acids, and glucose concentrations and of homeostasis model assessment of insulin resistance in a representative sample of Quebec children and adolescents. Clin. Chem. 49, 644–649 (2003)CrossRefPubMed P. Allard, E.E. Delvin, G. Paradis et al., Distribution of fasting plasma insulin, free fatty acids, and glucose concentrations and of homeostasis model assessment of insulin resistance in a representative sample of Quebec children and adolescents. Clin. Chem. 49, 644–649 (2003)CrossRefPubMed
Metadaten
Titel
Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance
verfasst von
Cheril L. Clarson
Farid H. Mahmud
Janet E. Baker
Helen E. Clark
Wendy M. Mckay
Vicki D. Schauteet
David J. Hill
Publikationsdatum
01.08.2009
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2009
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-009-9196-9

Weitere Artikel der Ausgabe 1/2009

Endocrine 1/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.